SERA vs TLRY · rev $77.0K vs rev $821.3M
Sera Prognostics Inc (SERA) versus Tilray Inc (TLRY) — a side-by-side from cached financials, not a winner call.
Sera Prognostics Inc (SERA) is a medical devices company listed on US.
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported SERA revenue for 2024-12-31 was $77.0K. Net income was -$32.9M. Revenue was down 74.8% from 2023-12-31 to 2024-12-31. SERA currently screens at market cap $89.1M.
Latest reported TLRY revenue for 2025-05-31 was $821.3M. Net income was -$2.18B. Revenue was up 4.1% from 2024-05-31 to 2025-05-31. TLRY currently screens at market cap $573.9M.
SERA currently screens at market cap $89.1M. TLRY currently screens at market cap $573.9M.
Not investment advice. Open the SERA and TLRY stock pages for the full models.
Not investment advice.